Drawing for EKOS TWINSTEP

USPTO serial 86584705

EKOS TWINSTEP

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
KHOURI, SANI PHILIPPE
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with EKOS TWINSTEP?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Jonathan A. Hyman

JONATHAN A. HYMAN Knobbe Martens Olson & Bear Llp2040 Main St Fl 14Irvine, CA 92614-8214UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical and medicinal preparations and substances for use in the prevention and treatment of circulatory system issues and conditions, pulmonary embolisms, thrombus, deep vein thrombosis, peripheral arterial occlusion, blood clots, vascular issues and conditions, and Intracranial Hemorrhages, cerebral hemorrages, and hematoma; Pharmaceutical and medicinal preparations and substances, namely, lysing solutions and reagents, and hemolytic lysing solutions and reagents; chemical reagents for medical therapeutic and diagnostic purposes; chemico-pharmaceutical preparations for use in the prevention and treatment of circulatory system issues and conditions, pulmonary embolisms, thrombus, deep vein thrombosis, peripheral arterial occlusion, blood clots, vascular issues and conditions, and Intracranial Hemorrhages, cerebral hemorrages, and hematoma; chemical preparations for medical or pharmaceutical purposes for use in the prevention and treatment of circulatory system issues and conditions, pulmonary embolisms, thrombus, deep vein thrombosis, peripheral arterial occlusion, blood clots, vascular issues and conditions, and Intracranial Hemorrhages, cerebral hemorrages, and hematoma; pharmaceutical preparations for use with ultrasound waves to enhance drug delivery and medically activate drugsACTIVE—
010Surgical apparatus and instruments; Medical apparatus and instruments for use in the prevention and treatment of circulatory system issues and conditions, pulmonary embolisms, thrombus, deep vein thrombosis, peripheral arterial occlusion, blood clots, vascular issues and conditions, and Intracranial Hemorrhages, cerebral hemorrages, and hematoma; Medical apparatus and instruments for use in the prevention and treatment of circulatory system issues and conditions, pulmonary embolisms, thrombus, deep vein thrombosis, peripheral arterial occlusion, blood clots, vascular issues and conditions, and Intracranial Hemorrhages, cerebral hemorrages, and hematoma and software sold as a unit therewith; drug delivery apparatus and instruments, namely, ultrasonic medical apparatus; Drug delivery apparatus and instruments, namely, ultrasonic medical apparatus and software sold as a unit therewith; Drug delivery systems; surgical and medical apparatus and instruments for use in treatment of the circulatory system; Medical apparatus and instruments for use in the prevention and treatment of the circulatory system issues and conditions, vascular issues and conditions, and Intracranial Hemorrhages, cerebral hemorrages, and hematoma; medical devices which use ultrasound to enhance drug delivery and medically activate drugs; catheters for delivery of drugs and fluids and controllers and power units for infusion catheters; ultrasonic drug delivery and drug activation apparatus and controllers and power units therefor; catheters; parts and fittings for all the aforesaid goodsACTIVE—
041Education services, namely, developing, arranging and conducting educational conferences and programmes and providing courses of instruction in the fields of healthcare, the use of pharmaceuticals and medical devices, medical research, surgery, medical science, medicine and in the fields of the prevention and treatment of circulatory system issues and conditions, pulmonary embolisms, thrombus, deep vein thrombosis, peripheral arterial occlusion, blood clots, vascular issues and conditions, and Intracranial Hemorrhages, cerebral hemorrages, and hematoma and distribution of course material in connection therewith; training in the use and operation of medical devices, medical ultrasound apparatus and medical research apparatus and consultation relating thereto; educational services, namely, conducting live and online seminars, classes, workshops, conferences, lectures, panel discussions, and training programs in the fields of health care and medical diseases, disorders and related treatments and in the fields of the prevention and treatment of circulatory system issues and conditions, pulmonary embolisms, thrombus, deep vein thrombosis, peripheral arterial occlusion, blood clots, vascular issues and conditions, and Intracranial Hemorrhages, cerebral hemorrages, and hematoma and distribution of course material in connection therewith; educational services, namely, providing non-downloadable webinars in the fields of health care and medical diseases, disorders and related treatments and in the fields of the prevention and treatment of circulatory system issues and conditions, pulmonary embolisms, thrombus, deep vein thrombosis, peripheral arterial occlusion, blood clots, vascular issues and conditions, and Intracranial Hemorrhages, cerebral hemorrages, and hematoma and distribution of course material in connection therewith; provision of educational content, namely, providing on-line instruction in the fields of health care and medical diseases, disorders and related treatments and in the fields of the prevention and treatment of circulatory system issues and conditions, pulmonary embolisms, thrombus, deep vein thrombosis, peripheral arterial occlusion, blood clots, vascular issues and conditions, and Intracranial Hemorrhages, cerebral hemorrages, and hematoma and distribution of course material in connection therewith; providing computer, electronic and on-line databases featuring information about medical education in the field of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care; advisory services in the fields of medical education; educational services, namely, conducting live and online seminars, classes, workshops, conferences, lectures, panel discussions and training in the fields of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine; educational services, namely, providing non-downloadable webinars in the fields of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and distribution of course material in connection therewith; non-downloadable electronic publications in the nature of teaching guides, instructional materials, brochures, and course books in the fields of healthcare, the use of pharmaceuticals and medical devices, medical research, surgery, medical science, medicine and in the fields of the prevention and treatment of circulatory system issues and conditions, pulmonary embolisms, thrombus, deep vein thrombosis, peripheral arterial occlusion, blood clots, vascular issues and conditions, and Intracranial Hemorrhages, cerebral hemorrages, and hematoma; electronic on-line databases featuring information about medical education in the field of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicineACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Jan 30, 2017MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jan 30, 2017ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
May 20, 2016EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
May 18, 2016EX1GSOU EXTENSION 1 GRANTED—
May 18, 2016EXT1SOU EXTENSION 1 FILED—
May 18, 2016EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Dec 29, 2015NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Nov 3, 2015NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Nov 3, 2015PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 14, 2015NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Sep 25, 2015PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Sep 18, 2015CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 16, 2015TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 16, 2015CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 10, 2015ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Jul 15, 2015GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Jul 15, 2015GNSLLETTER OF SUSPENSION E-MAILED—
Jul 15, 2015CNSLSUSPENSION LETTER WRITTEN—
Jul 8, 2015DOCKASSIGNED TO EXAMINER—
Jul 4, 2015AMPXPRELIMINARY/VOLUNTARY AMENDMENT - ENTERED—
Jun 30, 2015ALIEASSIGNED TO LIE—
Jun 19, 2015ALIEASSIGNED TO LIE—
Jun 11, 2015PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Apr 14, 2015MPMKNOTICE OF PSEUDO MARK E-MAILED—
Apr 11, 2015NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 4, 2015NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance